S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
66,000% upside on tiny biotech? (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
66,000% upside on tiny biotech? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
66,000% upside on tiny biotech? (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
66,000% upside on tiny biotech? (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
66,000% upside on tiny biotech? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
66,000% upside on tiny biotech? (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
66,000% upside on tiny biotech? (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
66,000% upside on tiny biotech? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
66,000% upside on tiny biotech? (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
66,000% upside on tiny biotech? (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
66,000% upside on tiny biotech? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
66,000% upside on tiny biotech? (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
Top-Rated StocksTop-RatedPositive News SentimentPositive News
NASDAQ:LEGN

Legend Biotech (LEGN) Stock Forecast, Price & News

$64.76
-0.14 (-0.22%)
(As of 10/3/2023 ET)
Compare
Today's Range
$61.31
▼
$65.25
50-Day Range
$63.16
▼
$76.50
52-Week Range
$37.30
▼
$77.32
Volume
800,720 shs
Average Volume
694,253 shs
Market Capitalization
$10.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$80.90
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Legend Biotech MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.87 Rating Score
Upside/​Downside
24.9% Upside
$80.90 Price Target
Short Interest
Bearish
4.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.89mentions of Legend Biotech in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.60) to ($1.61) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

879th out of 966 stocks

Pharmaceutical Preparations Industry

398th out of 436 stocks

See Top Rated MarketRank™ Stocks Here

LEGN stock logo

About Legend Biotech (NASDAQ:LEGN) Stock

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia , gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

LEGN Price History

LEGN Stock News Headlines

October 3, 2023 | insidermonkey.com
Legend Biotech Corporation (LEGN)’s Stock Witnessed a 43% Increase in Q2
September 25, 2023 | americanbankingnews.com
Legend Biotech Co. (NASDAQ:LEGN) Receives $80.90 Average Target Price from Analysts
October 4, 2023 | Oxford Club (Ad)
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
August 21, 2023 | seekingalpha.com
Legend Biotech: Working On Supply Issues
August 16, 2023 | markets.businessinsider.com
Legend Biotech (LEGN) Receives a Buy from Barclays
August 16, 2023 | finance.yahoo.com
Q2 2023 Legend Biotech Corp Earnings Call
August 15, 2023 | finance.yahoo.com
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
August 14, 2023 | finance.yahoo.com
Why Earnings Season Could Be Great for Legend Biotech (LEGN)
October 4, 2023 | Oxford Club (Ad)
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
August 3, 2023 | finance.yahoo.com
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
July 21, 2023 | msn.com
Morgan Stanley Maintains Legend Biotech Corp - ADR (LEGN) Overweight Recommendation
July 7, 2023 | seekingalpha.com
Despite High Share Price, Legend Bio Looks Like A Winner
June 29, 2023 | finance.yahoo.com
This Top-Performing Small-Cap Manager Is Betting Big on China
June 12, 2023 | markets.businessinsider.com
BTIG Keeps Their Buy Rating on Legend Biotech (LEGN)
June 7, 2023 | markets.businessinsider.com
Piper Sandler Reaffirms Their Buy Rating on Legend Biotech (LEGN)
June 7, 2023 | finance.yahoo.com
Legend (LEGN) Up 4% on sNDA Submission for Carvykti Expanded Use
June 7, 2023 | msn.com
HC Wainwright & Co. Maintains Legend Biotech Corp - ADR (LEGN) Buy Recommendation
June 6, 2023 | finance.yahoo.com
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
June 5, 2023 | finance.yahoo.com
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
May 25, 2023 | markets.businessinsider.com
Expert Ratings for Legend Biotech
May 25, 2023 | msn.com
William Blair Initiates Coverage of Legend Biotech Corp - ADR (LEGN) with Market Perform Recommendation
May 25, 2023 | finance.yahoo.com
Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
May 23, 2023 | finance.yahoo.com
Legend Biotech's Story Is Still Playing Out
May 22, 2023 | msn.com
HC Wainwright & Co. Reiterates Legend Biotech Corp - ADR (LEGN) Buy Recommendation
May 22, 2023 | msn.com
Daiwa Capital Initiates Coverage of Legend Biotech Corp - ADR (LEGN) with Buy Recommendation
May 19, 2023 | msn.com
Barclays Maintains Legend Biotech Corp - ADR (LEGN) Overweight Recommendation
May 19, 2023 | msn.com
RBC Capital Maintains Legend Biotech Corp - ADR (LEGN) Outperform Recommendation
See More Headlines
Receive LEGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter.

LEGN Company Calendar

Last Earnings
8/15/2023
Today
10/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LEGN
CUSIP
N/A
CIK
1801198
Web
www.legendbiotech.com
Phone
732-317-5050
Fax
N/A
Employees
1,390
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$80.90
High Stock Price Forecast
$92.00
Low Stock Price Forecast
$64.00
Forecasted Upside/Downside
+24.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
8.01
Quick Ratio
7.93

Sales & Book Value

Annual Sales
$117 million
Price / Sales
91.37
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.54 per share
Price / Book
14.26

Miscellaneous

Outstanding Shares
165,070,000
Free Float
165,034,000
Market Cap
$10.69 billion
Optionable
Not Optionable
Beta
0.06
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Ying Huang Ph.D. (Age 50)
    CEO & Director
  • Ms. Lori A. Macomber CPA (Age 52)
    Chief Financial Officer
  • Dr. Guowei Fang Ph.D.
    Chief Scientific Officer & Head of Bus. Devel.
  • Joanne Choi
    Sr. Mang. of Investor Relations
  • Deborah Wong
    Exec. Director of Strategic Marketing & Corp. Communications
  • Ms. Elaine Qian
    VP & Global Head of HR
  • Ms. Liz Gosen
    Sr. VP of Technical Operations
  • Dr. Yuhong Qiu Ph.D.
    Sr. VP of Global Regulatory Affairs
  • Mr. Steven J. Gavel
    Sr. VP of Commercial Devel., US & Europe
  • Mr. Alan Kick
    Sr. VP of Global Quality

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













LEGN Stock - Frequently Asked Questions

Should I buy or sell Legend Biotech stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LEGN shares.
View LEGN analyst ratings or view top-rated stocks.

What is Legend Biotech's stock price forecast for 2023?

15 equities research analysts have issued 12 month target prices for Legend Biotech's stock. Their LEGN share price forecasts range from $64.00 to $92.00. On average, they predict the company's share price to reach $80.90 in the next year. This suggests a possible upside of 24.9% from the stock's current price.
View analysts price targets for LEGN or view top-rated stocks among Wall Street analysts.

How have LEGN shares performed in 2023?

Legend Biotech's stock was trading at $49.92 on January 1st, 2023. Since then, LEGN stock has increased by 29.7% and is now trading at $64.76.
View the best growth stocks for 2023 here.

How were Legend Biotech's earnings last quarter?

Legend Biotech Co. (NASDAQ:LEGN) issued its quarterly earnings results on Tuesday, August, 15th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.21. The firm earned $73.30 million during the quarter, compared to analysts' expectations of $56.64 million. The firm's revenue was up 510.8% on a year-over-year basis.

What ETFs hold Legend Biotech's stock?

ETFs with the largest weight of Legend Biotech (NASDAQ:LEGN) stock in their portfolio include Global X MSCI China Health Care ETF (CHIH), Loncar China BioPharma ETF (CHNA), Harbor Health Care ETF (MEDI), Virtus LifeSci Biotech Products ETF (BBP), KraneShares MSCI All China Health Care Index ETF (KURE), Fidelity Disruptive Medicine ETF (FMED), BlackRock Future Health ETF (BMED) and Range Cancer Therapeutics ETF (CNCR).

What other stocks do shareholders of Legend Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY).

When did Legend Biotech IPO?

(LEGN) raised $350 million in an initial public offering on Friday, June 5th 2020. The company issued 18,400,000 shares at $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO.

What is Legend Biotech's stock symbol?

Legend Biotech trades on the NASDAQ under the ticker symbol "LEGN."

How do I buy shares of Legend Biotech?

Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Legend Biotech's stock price today?

One share of LEGN stock can currently be purchased for approximately $64.76.

How much money does Legend Biotech make?

Legend Biotech (NASDAQ:LEGN) has a market capitalization of $10.69 billion and generates $117 million in revenue each year.

How many employees does Legend Biotech have?

The company employs 1,390 workers across the globe.

How can I contact Legend Biotech?

Legend Biotech's mailing address is 2101 COTTONTAIL LANE, SOMERSET NJ, 08873. The official website for the company is www.legendbiotech.com. The company can be reached via phone at 732-317-5050 or via email at investor@legendbiotech.com.

This page (NASDAQ:LEGN) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -